{"name":"MedImmune LLC","slug":"medimmune-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":31,"colorKey":"oncology","drugs":[{"name":"CAIV-T 10^7","genericName":"CAIV-T 10^7","slug":"caiv-t-10-7","indication":"Influenza prevention","status":"phase_2"},{"name":"CAIV-T, Liquid","genericName":"CAIV-T, Liquid","slug":"caiv-t-liquid","indication":"Seasonal influenza prevention in children and adults","status":"phase_3"},{"name":"CAIVT","genericName":"CAIVT","slug":"caivt","indication":"Influenza prevention in pediatric and adult populations","status":"phase_3"},{"name":"Trivalent Influenza Virus Vaccine","genericName":"Trivalent Influenza Virus Vaccine","slug":"trivalent-influenza-virus-vaccine","indication":"Other","status":"marketed"},{"name":"ACP-501","genericName":"ACP-501","slug":"acp-501","indication":"Other","status":"phase_1"},{"name":"AV024","genericName":"AV024","slug":"av024","indication":"Systemic sclerosis (scleroderma)","status":"phase_3"},{"name":"Bivalent influenza vaccine","genericName":"Bivalent influenza vaccine","slug":"bivalent-influenza-vaccine","indication":"Other","status":"marketed"},{"name":"CAIV-T","genericName":"CAIV-T","slug":"caiv-t","indication":"Seasonal influenza prevention in children and adults","status":"phase_3"},{"name":"CAIV-T and TIV","genericName":"CAIV-T and TIV","slug":"caiv-t-and-tiv","indication":"Seasonal influenza prevention in pediatric and/or adult populations","status":"phase_3"},{"name":"CAIV-T or TIV","genericName":"CAIV-T or TIV","slug":"caiv-t-or-tiv","indication":"Seasonal influenza prevention in children and adults aged 2-49 years","status":"phase_3"},{"name":"FluMist Quadrivalent (2017-2018)","genericName":"FluMist Quadrivalent (2017-2018)","slug":"flumist-quadrivalent-2017-2018","indication":"Other","status":"marketed"},{"name":"FluMist trivalent (2015-2016)","genericName":"FluMist trivalent (2015-2016)","slug":"flumist-trivalent-2015-2016","indication":"Influenza prevention in children and adults aged 2-49 years","status":"marketed"},{"name":"FluMist, Influenza Virus Vaccine Live","genericName":"FluMist, Influenza Virus Vaccine Live","slug":"flumist-influenza-virus-vaccine-live","indication":"Influenza prophylaxis in children and adults aged 2-49 years","status":"phase_2"},{"name":"FluMist/B/Victoria","genericName":"FluMist/B/Victoria","slug":"flumist-b-victoria","indication":"Influenza prevention in children and adults (seasonal influenza prophylaxis)","status":"phase_3"},{"name":"FluMist/B/Yamagata","genericName":"FluMist/B/Yamagata","slug":"flumist-b-yamagata","indication":"Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations","status":"phase_3"},{"name":"Frozen FluMist®","genericName":"Frozen FluMist®","slug":"frozen-flumist","indication":"Other","status":"phase_2"},{"name":"ICE","genericName":"ICE","slug":"ice","indication":"Other","status":"marketed"},{"name":"Liquid CAIV-T","genericName":"Liquid CAIV-T","slug":"liquid-caiv-t","indication":"Seasonal influenza prevention in children and adults aged 2-49 years","status":"phase_3"},{"name":"Lyophilized Palivizumab","genericName":"Lyophilized Palivizumab","slug":"lyophilized-palivizumab","indication":"Other","status":"marketed"},{"name":"MEDI-545","genericName":"MEDI-545","slug":"medi-545","indication":"Other","status":"phase_2"},{"name":"MEDI0639","genericName":"MEDI0639","slug":"medi0639","indication":"Other","status":"phase_1"},{"name":"MEDI4893","genericName":"MEDI4893","slug":"medi4893","indication":"Other","status":"phase_2"},{"name":"MEDI5395","genericName":"MEDI5395","slug":"medi5395","indication":"Other","status":"phase_1"},{"name":"MEDI8897 50 mg","genericName":"MEDI8897 50 mg","slug":"medi8897-50-mg","indication":"Other","status":"phase_1"},{"name":"Monovalent Frozen FluMist®","genericName":"Monovalent Frozen FluMist®","slug":"monovalent-frozen-flumist","indication":"Other","status":"marketed"},{"name":"Monovalent Influenza Vaccine","genericName":"Monovalent Influenza Vaccine","slug":"monovalent-influenza-vaccine","indication":"Other","status":"marketed"},{"name":"Monovalent influenza virus vaccine","genericName":"Monovalent influenza virus vaccine","slug":"monovalent-influenza-virus-vaccine","indication":"Other","status":"marketed"},{"name":"Q/LAIV (MEDI3250)","genericName":"Q/LAIV (MEDI3250)","slug":"q-laiv-medi3250","indication":"Seasonal influenza prevention in pediatric and adult populations","status":"phase_3"},{"name":"Q/LAIV-BFS (MEDI8662)","genericName":"Q/LAIV-BFS (MEDI8662)","slug":"q-laiv-bfs-medi8662","indication":"Prevention of influenza A and B in children and adults","status":"phase_3"},{"name":"RSV sF 50 mcg","genericName":"RSV sF 50 mcg","slug":"rsv-sf-50-mcg","indication":"Other","status":"phase_1"},{"name":"Trivalent Influenza Vaccine","genericName":"Trivalent Influenza Vaccine","slug":"trivalent-influenza-vaccine","indication":"Seasonal influenza prevention in adults and children ≥6 months of age","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Liquid Palivizumab","genericName":"Liquid Palivizumab","slug":"liquid-palivizumab","indication":"Prevention of respiratory syncytial virus (RSV) disease in high-risk infants and young children, including those with congenital heart disease, chronic lung disease, or immunodeficiency","status":"marketed"},{"name":"MEDI-546","genericName":"MEDI-546","slug":"medi-546","indication":"Systemic lupus erythematosus (SLE)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"MEDI8897","genericName":"MEDI8897","slug":"medi8897","indication":"Prevention of respiratory syncytial virus (RSV) disease in infants born during RSV season","status":"phase_3"},{"name":"motavizumab (MEDI-524)","genericName":"motavizumab (MEDI-524)","slug":"motavizumab-medi-524","indication":"Prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAIVT 10^5","genericName":"CAIVT 10^5","slug":"caivt-10-5","indication":"Respiratory syncytial virus infection","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dapaglifozin","genericName":"Dapaglifozin","slug":"dapaglifozin","indication":"Chronic heart failure","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"MEDI4736","genericName":"MEDI4736","slug":"medi4736","indication":"Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy","status":"phase_3"}]}],"pipeline":[{"name":"CAIV-T 10^7","genericName":"CAIV-T 10^7","slug":"caiv-t-10-7","phase":"phase_2","mechanism":"CAIV-T 10^7 is a live attenuated influenza vaccine.","indications":["Influenza prevention"],"catalyst":""},{"name":"CAIV-T, Liquid","genericName":"CAIV-T, Liquid","slug":"caiv-t-liquid","phase":"phase_3","mechanism":"CAIV-T is a live attenuated influenza vaccine administered as a nasal spray that stimulates mucosal and systemic immune responses against influenza.","indications":["Seasonal influenza prevention in children and adults"],"catalyst":""},{"name":"CAIVT","genericName":"CAIVT","slug":"caivt","phase":"phase_3","mechanism":"CAIVT is a live attenuated influenza vaccine designed to provide broad protection against multiple influenza virus strains through intranasal delivery.","indications":["Influenza prevention in pediatric and adult populations"],"catalyst":""},{"name":"Trivalent Influenza Virus Vaccine","genericName":"Trivalent Influenza Virus Vaccine","slug":"trivalent-influenza-virus-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ACP-501","genericName":"ACP-501","slug":"acp-501","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AV024","genericName":"AV024","slug":"av024","phase":"phase_3","mechanism":"AV024 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses.","indications":["Systemic sclerosis (scleroderma)","Other fibrotic or inflammatory conditions"],"catalyst":""},{"name":"Bivalent influenza vaccine","genericName":"Bivalent influenza vaccine","slug":"bivalent-influenza-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CAIV-T","genericName":"CAIV-T","slug":"caiv-t","phase":"phase_3","mechanism":"CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.","indications":["Seasonal influenza prevention in children and adults"],"catalyst":""},{"name":"CAIV-T and TIV","genericName":"CAIV-T and TIV","slug":"caiv-t-and-tiv","phase":"phase_3","mechanism":"CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains.","indications":["Seasonal influenza prevention in pediatric and/or adult populations"],"catalyst":""},{"name":"CAIV-T or TIV","genericName":"CAIV-T or TIV","slug":"caiv-t-or-tiv","phase":"phase_3","mechanism":"CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.","indications":["Seasonal influenza prevention in children and adults aged 2-49 years"],"catalyst":""},{"name":"CAIVT 10^5","genericName":"CAIVT 10^5","slug":"caivt-10-5","phase":"phase_2","mechanism":"CAIVT 10^5 is a live attenuated virus vaccine.","indications":["Respiratory syncytial virus infection"],"catalyst":""},{"name":"Dapaglifozin","genericName":"Dapaglifozin","slug":"dapaglifozin","phase":"phase_3","mechanism":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","indications":["Chronic heart failure","Chronic kidney disease","Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"FluMist Quadrivalent (2017-2018)","genericName":"FluMist Quadrivalent (2017-2018)","slug":"flumist-quadrivalent-2017-2018","phase":"marketed","mechanism":"FluMist Quadrivalent is a live attenuated influenza vaccine that stimulates an immune response in the nasal passages to prevent influenza infection.","indications":[],"catalyst":""},{"name":"FluMist trivalent (2015-2016)","genericName":"FluMist trivalent (2015-2016)","slug":"flumist-trivalent-2015-2016","phase":"marketed","mechanism":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened flu virus strains intranasally.","indications":["Influenza prevention in children and adults aged 2-49 years"],"catalyst":""},{"name":"FluMist, Influenza Virus Vaccine Live","genericName":"FluMist, Influenza Virus Vaccine Live","slug":"flumist-influenza-virus-vaccine-live","phase":"phase_2","mechanism":"FluMist is a live attenuated influenza vaccine that replicates in the nasal mucosa to stimulate local and systemic immune responses against influenza viruses.","indications":["Influenza prophylaxis in children and adults aged 2-49 years"],"catalyst":""},{"name":"FluMist/B/Victoria","genericName":"FluMist/B/Victoria","slug":"flumist-b-victoria","phase":"phase_3","mechanism":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally.","indications":["Influenza prevention in children and adults (seasonal influenza prophylaxis)"],"catalyst":""},{"name":"FluMist/B/Yamagata","genericName":"FluMist/B/Yamagata","slug":"flumist-b-yamagata","phase":"phase_3","mechanism":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally.","indications":["Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations"],"catalyst":""},{"name":"Frozen FluMist®","genericName":"Frozen FluMist®","slug":"frozen-flumist","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ICE","genericName":"ICE","slug":"ice","phase":"marketed","mechanism":"ICE is an intracellular caspase inhibitor that blocks apoptosis by inhibiting caspase enzymes responsible for programmed cell death.","indications":[],"catalyst":""},{"name":"Liquid CAIV-T","genericName":"Liquid CAIV-T","slug":"liquid-caiv-t","phase":"phase_3","mechanism":"Liquid CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.","indications":["Seasonal influenza prevention in children and adults aged 2-49 years"],"catalyst":""},{"name":"Liquid Palivizumab","genericName":"Liquid Palivizumab","slug":"liquid-palivizumab","phase":"marketed","mechanism":"Palivizumab is a monoclonal antibody that binds to the fusion (F) protein on the surface of respiratory syncytial virus (RSV), preventing viral attachment and entry into host cells.","indications":["Prevention of respiratory syncytial virus (RSV) disease in high-risk infants and young children, including those with congenital heart disease, chronic lung disease, or immunodeficiency"],"catalyst":""},{"name":"Lyophilized Palivizumab","genericName":"Lyophilized Palivizumab","slug":"lyophilized-palivizumab","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MEDI-545","genericName":"MEDI-545","slug":"medi-545","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MEDI-546","genericName":"MEDI-546","slug":"medi-546","phase":"phase_3","mechanism":"MEDI-546 is a monoclonal antibody that targets and inhibits B-cell activating factor (BAFF) to reduce B-cell proliferation and autoimmune responses.","indications":["Systemic lupus erythematosus (SLE)","Rheumatoid arthritis"],"catalyst":""},{"name":"MEDI0639","genericName":"MEDI0639","slug":"medi0639","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MEDI4736","genericName":"MEDI4736","slug":"medi4736","phase":"phase_3","mechanism":"MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.","indications":["Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy","Metastatic or unresectable locally advanced urothelial carcinoma","Metastatic gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"MEDI4893","genericName":"MEDI4893","slug":"medi4893","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MEDI5395","genericName":"MEDI5395","slug":"medi5395","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MEDI8897","genericName":"MEDI8897","slug":"medi8897","phase":"phase_3","mechanism":"MEDI8897 is a monoclonal antibody that provides extended half-life neutralization of respiratory syncytial virus (RSV) through engineered Fc region modifications.","indications":["Prevention of respiratory syncytial virus (RSV) disease in infants born during RSV season","Prevention of RSV disease in older adults"],"catalyst":""},{"name":"MEDI8897 50 mg","genericName":"MEDI8897 50 mg","slug":"medi8897-50-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Monovalent Frozen FluMist®","genericName":"Monovalent Frozen FluMist®","slug":"monovalent-frozen-flumist","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Monovalent Influenza Vaccine","genericName":"Monovalent Influenza Vaccine","slug":"monovalent-influenza-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Monovalent influenza virus vaccine","genericName":"Monovalent influenza virus vaccine","slug":"monovalent-influenza-virus-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Q/LAIV (MEDI3250)","genericName":"Q/LAIV (MEDI3250)","slug":"q-laiv-medi3250","phase":"phase_3","mechanism":"Q/LAIV is a live attenuated influenza vaccine (LAIV) engineered with a reassortant backbone to provide broad protection against seasonal influenza strains.","indications":["Seasonal influenza prevention in pediatric and adult populations"],"catalyst":""},{"name":"Q/LAIV-BFS (MEDI8662)","genericName":"Q/LAIV-BFS (MEDI8662)","slug":"q-laiv-bfs-medi8662","phase":"phase_3","mechanism":"Q/LAIV-BFS is a quadrivalent live attenuated influenza vaccine formulated in a pre-filled, single-dose applicator for intranasal administration.","indications":["Prevention of influenza A and B in children and adults"],"catalyst":""},{"name":"RSV sF 50 mcg","genericName":"RSV sF 50 mcg","slug":"rsv-sf-50-mcg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Trivalent Influenza Vaccine","genericName":"Trivalent Influenza Vaccine","slug":"trivalent-influenza-vaccine","phase":"marketed","mechanism":"The trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection.","indications":["Seasonal influenza prevention in adults and children ≥6 months of age"],"catalyst":""},{"name":"motavizumab (MEDI-524)","genericName":"motavizumab (MEDI-524)","slug":"motavizumab-medi-524","phase":"phase_3","mechanism":"Motavizumab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F-protein.","indications":["Prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQY20xUElOVjYxMjRlMDFqQkktODRIMWtFU0g3VUIxQWk0ei1wOHlKdnhVWXJKWDRNaS1sSUduVnI3R0N2TkV1WE1ORmtMbEtUelZITWg4X0c5RkRyVHpZWmxkSTFWc29QajV2VHppU1NncHhYLTdWWGJ0eUVkby1MYm82bVllUG1uVlVSakFSazRmQVJjaklDeUJKMA?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Mesothelioma Clinical Trial Pipeline Appears Robust With 45+ - openPR.com","headline":"Mesothelioma Clinical Trial Pipeline Appears Robust With 45+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNdEk1YVVkRHR5Ql81djI1ZlpsclRCMVU5U1V2TjQ3MjBzVnNGTzFDSDlaTG5TVUtoSW1WOGZIOEhFVUJBTWw1eURiUFc4UElGRGtCa1lGRklWaHVjRVdjd045OHR3YkN5QzRPQ2NLNXdXR2d4OW5kSURHQnI0c0Y5WFU5S3FhVDd6YWp2UGlQVlZkc0lFQzdSRTNIMDB1TUo0ZmJn?oc=5","date":"2025-12-01","type":"pipeline","source":"Contract Pharma","summary":"Vistagen Names Nick Tressler as Chief Financial Officer - Contract Pharma","headline":"Vistagen Names Nick Tressler as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOVVtaG5tcXJqUmd1OG9zZWhjQXNFdXhIek4zSTlsVkpGQVVOa0Jkd2ZoWHlPcWliY211WlRKbEQtNWkzVUlGR2FRd0Q5VmNxaGhiTXFvTFpOb1RUYm1uWHNTTWtwYVpFMWVZbHlSS1Y3aXF2TDNlR3BKcWtoUm93ckJlZDJiMWtEUmgwUUNmcHBXOTUyUGFlOUUtb280czVlbjBOWTR6TVFpQQ?oc=5","date":"2025-03-18","type":"deal","source":"BioWorld News","summary":"Alteogen in $1.35B Medimmune deal; Astrazeneca bids $1B for Esobiotec - BioWorld News","headline":"Alteogen in $1.35B Medimmune deal; Astrazeneca bids $1B for Esobiotec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPbU05a0JvUV85Yk12MzdkYmFKay01VmxlYTBvbUdZbHU4WjRsam9lSlVnZjlJY2FaRHlVMDM3V2ZlRHFNc2VSVEtVc0toZ1B2bEd0VzlCY01zSzZMV0Q3X0pUbmpzOE1fREJ4Rkdhb0JtZ0wwel9MaF9tY2lxbFBWM1ZaYmI4eWc?oc=5","date":"2024-12-20","type":"trial","source":"Stock Titan","summary":"Aridis Pharma Secures $6.5M Asset Deal for AR-501, Advances Phase 3 Investment Plans - Stock Titan","headline":"Aridis Pharma Secures $6.5M Asset Deal for AR-501, Advances Phase 3 Investment Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNRzhLTzM0c0gwMW9keXd3RWRwUnNBQmh1ZWNhUVlia3NLN0ktVk9TUkFNZ2FjcEkyMnh2TU9ZaDdwTzROWVlPZ3RYQkYzbjJmNWlib0FVeW1IVzR1Rk9CUjl1UC1rSy1tdlVEUFlfZjRuQ3FxYTdNcUJvaWN1ZlFOdjVqQ3cyOTB0UnJwVU8xNXp5TWZLNzYySW1iaXN2c0pVM3owSHVjZGVSNmFG?oc=5","date":"2023-04-03","type":"pipeline","source":"Fierce Biotech","summary":"Reeling from AstraZeneca's termination of pneumonia collab, Aridis lays off 20% of staff - Fierce Biotech","headline":"Reeling from AstraZeneca's termination of pneumonia collab, Aridis lays off 20% of staff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQeEhyX3ctT2tBRG92RXhMWUFLeHdjV0RTXzIycHllU3BVNWpSd0hvdUN5dExDdWx2Q1NCWFJ2NWM5SWlqVkl0RXFEN2l4SHZCdmxYNnR3ejRBT0ZOa0hPU3ZsbUZ1bzRObE1TMHYyeXJ0NU9JNjZjODludjhCcjdaRmdwd0RnS29YdDZzRUg3ZmdXV2dfU1lhS0dBTmZPMHlv?oc=5","date":"2019-02-14","type":"pipeline","source":"BioPharma Dive","summary":"AstraZeneca retires Medimmune name amid sales turnaround - BioPharma Dive","headline":"AstraZeneca retires Medimmune name amid sales turnaround","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSlZpc0YzX0tqZEpXUml6QlNYcGRiVjB6VWZhV0NFTDJmTjFDdlBhMjgyUlNZMDNVMWxsUzNJODlyQWZrOHhEanpjLWsxenM4cEliTmF1b1g5dk10RlVNZkRoQXFnODZneHAzLU8ydVpEejNsdlRtOWp6dGNmYmpzTk9lLWZoeEJxa3JSVVdWYlR3VlNoeG1UcUk3VjhsS1ZHQVkyaXI5UFI?oc=5","date":"2018-02-28","type":"pipeline","source":"BioSpace","summary":"Viela Bio Spins Out of AstraZeneca’s MedImmune with $250 Million Series A Funding - BioSpace","headline":"Viela Bio Spins Out of AstraZeneca’s MedImmune with $250 Million Series A Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOS0l5cEgzZVUyQ3VwNlhHRDYxZlAtN0RKRE5RNExKMnlUYmZDNEN1WktTbDRIMjE1VHFLbWYzdVRCTDFaLW9WNVl6VlM0MHcxNkJGTTV6UmFkRzJtbGpMVEdYSlpWOExUX012czVaZzE4UHE2UGhpX3NhbEtvU3YyUlVDZTBaVEtlTEFVb1g4cGxXOUY2Y19sNmtXQUhTN3JvcW5lanlOeUxSc3p0SnRTU3lEYWUtN2dHYnpWNWhlMHItNi1PUmtPUUN1WnlFMHZWcEdWdkFkSC03RWQtT2JUcVRJckR6MHFQcEE?oc=5","date":"2016-10-03","type":"deal","source":"AstraZeneca","summary":"MedImmune out-licenses potential medicine for inflammatory diseases to Allergan - AstraZeneca","headline":"MedImmune out-licenses potential medicine for inflammatory diseases to Allergan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTXIwaXNSQjJHUXB6WFZkUTE3QV9rTjA0SjFXTG12OXZVS3NCTzN4ejhtanppdDgzaktXOXdpazZCSjZCd241OFZmclphWGZydTdYVHFsZWNZUkhhZjRVRjBhR0RuUENDSjU3QXN2YURLZFpwTmhnSVdmcnNHby1Fbm8tS3AzRWdNVzdEWm1NWFRpMmhrRmZzbHp2WDZzRWs4WlZib05NZnJfUzA4U3lIdVhYb2dMR0Q1MTlENENZTXY?oc=5","date":"2013-04-03","type":"deal","source":"AstraZeneca","summary":"MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma - AstraZeneca","headline":"MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQYzlNck5uaVNBN21RTEF2UnoyeUNfSm1QZ242ZnRzbHRYZFBCTGlDWmtDU21iNHNId1hGS1BzeUY4ZG9FRFhPX25IMUZONXk5SWpSTDN4WlNMT1Vjc3J1emxWVUVRYXNRekZJUjBBZW1XVjFHR0ozd0xoS1d4d0RoYzVFV21hMG03LU5peG5PekxBN2I0NkJ2dmkyN0FQdjQ?oc=5","date":"2012-04-18","type":"trial","source":"Clinical Trials Arena","summary":"Small players, big drugs – pharmaceutical SMEs take the innovative edge - Clinical Trials Arena","headline":"Small players, big drugs – pharmaceutical SMEs take the innovative edge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9sQWx0NFEzdmRUMXBCVkF2N1hlMEhFbUhfVUd0UEY0eEppTXlmb0hQZW5LNHpQOTdZdEdoZHk3RWR0cnVQUGpRYUEzZVBTTlVTM1J6eUU1b25nTkxsejNxYVJBSEpJcW10aEVZbjUtdVN4RVpR?oc=5","date":"2007-10-14","type":"pipeline","source":"Pharmaceutical Technology","summary":"Medimmune, Biologics Manufacturing Facility - Pharmaceutical Technology","headline":"Medimmune, Biologics Manufacturing Facility","sentiment":"neutral"}],"patents":[],"drugCount":38,"phaseCounts":{"phase_2":6,"phase_3":16,"marketed":11,"phase_1":5},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}